Stage IV Prostate Cancer Clinical Trial
Official title:
A Prospective Multi-center Study to Compare the QOL and Efficacy of Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer.
This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with endocrine therapy with or without cryoablation.
OBJECTIVES:
- To determine the tumor control in patients with prostate cancer treated with
radiotherapy or cryoablation
- To determine the quality of life of these patients. OUTLINE: This is a multicenter
study. Patients are stratified according to Gleason score (≥ 8 vs 7 vs ≤ 6), persistent
prostatic specific antigen (PSA) at allocation (> 0.5 ng/mL vs ≤ 0.5 ng/mL),
participating center. Patient are allocated to two treatment arms.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT01685125 -
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00936975 -
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
|
Phase 2 | |
Completed |
NCT00087139 -
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03511196 -
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
|
Early Phase 1 | |
Completed |
NCT01881867 -
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01385059 -
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02807805 -
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01026623 -
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01682941 -
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
|
N/A | |
Terminated |
NCT00536991 -
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03707184 -
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
|
Phase 2 | |
Withdrawn |
NCT00003534 -
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04113096 -
Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT03344211 -
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT02985021 -
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
|
Phase 2 | |
Terminated |
NCT00527124 -
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 |